|
gptkbp:instanceOf
|
gptkb:drug
antipsychotic medication
|
|
gptkbp:approvedBy
|
gptkb:FDA
2015
|
|
gptkbp:ATCCode
|
N05AX16
|
|
gptkbp:CASNumber
|
913611-97-9
|
|
gptkbp:chemicalFormula
|
C25H27N3O2S
|
|
gptkbp:developedBy
|
gptkb:Otsuka_Pharmaceutical
gptkb:Lundbeck
|
|
gptkbp:drugClass
|
antipsychotic medication
|
|
gptkbp:eliminationHalfLife
|
91 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
brexpiprazole
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:Rexulti
|
|
gptkbp:mechanismOfAction
|
antagonist at serotonin 5-HT2A receptors
partial agonist at dopamine D2 receptors
partial agonist at serotonin 5-HT1A receptors
|
|
gptkbp:metabolism
|
liver (CYP3A4, CYP2D6)
|
|
gptkbp:molecularWeight
|
433.57 g/mol
|
|
gptkbp:pregnancyCategory
|
C
|
|
gptkbp:relatedTo
|
gptkb:aripiprazole
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
dizziness
headache
weight gain
insomnia
akathisia
|
|
gptkbp:usedFor
|
gptkb:major_depressive_disorder
schizophrenia
|
|
gptkbp:bfsParent
|
gptkb:Rexulti
gptkb:N05AX
gptkb:5-HT2C_receptor
|
|
gptkbp:bfsLayer
|
7
|